NeuroBo Pharmaceuticals, Inc. Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2022. The filing is an annual report, not a quarterly Form 10-Q, despite the request metadata referring to “2022 Q4.” NeuroBo is a clinical-stage biotechnology company focused on cardiometabolic diseases.
Business Context
NeuroBo’s primary programs are DA-1241, an oral GPR119 agonist being developed for NASH and type 2 diabetes, and DA-1726, a once-weekly GLP1R/GCGR dual agonist being developed for NASH and obesity. The company also retains legacy programs, but management has prioritized DA-1241 and DA-1726 and may pursue licensing or acquisition opportunities for the legacy assets.
In November 2022, NeuroBo’s exclusive global license from Dong-A ST became effective for DA-1241 and DA-1726, excluding South Korea. The transaction also established Dong-A as the required manufacturer of clinical quantities of both compounds.
Financial Performance and Position
| Metric | 2022 | 2021 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | No change |
| Research and development expense | $2.8 million | $6.5 million | Down $3.8 million |
| Acquired in-process R&D | $8.2 million | $0 | Up $8.2 million |
| General and administrative expense | $8.6 million | $8.8 million | Down $0.1 million |
| Total operating expenses | $19.6 million | $15.3 million | Up $4.3 million |
| Net loss | $14.0 million | $15.3 million | Improved by $1.3 million |
| Net loss per share | $5.43 | $19.81 | Improved |
| Net cash used in operating activities | $11.7 million | $15.1 million | Improved by $3.4 million |
| Cash at year-end | $33.4 million | $16.4 million | Up $17.0 million |
The 2022 net loss included an $8.2 million non-cash acquired in-process R&D charge for the Dong-A license, $2.2 million of financing expense, and a $7.9 million gain from the change in fair value of warrant liabilities. The company had no product, collaboration, grant or other operating revenue.
At December 31, 2022, total assets were $33.5 million, total liabilities were $11.8 million, stockholders’ equity was $21.8 million, and accumulated deficit was $95.8 million. Warrant liabilities were $10.8 million. The company reported no conventional debt balance in the financial statements provided.
Net cash provided by financing activities was $28.7 million, reflecting approximately $17.3 million of gross proceeds from the public offering and $15.0 million from the Dong-A financing, partially offset by $3.6 million of issuance costs. Management stated that available cash was expected to fund operations into 2024, but additional financing will be required before sustainable product revenue is generated.
Material Changes Versus 2021
- NeuroBo shifted its strategic focus to DA-1241 and DA-1726 after entering the Dong-A license and related services agreements.
- Research and development spending declined as the ANA001 clinical trial was completed and clinical, manufacturing, payroll and consulting activity decreased.
- Total operating expenses increased because of the $8.2 million non-cash license-related IPR&D charge.
- Cash increased materially following the November 2022 public offering and Dong-A financing.
- Shares outstanding increased substantially through the conversion of preferred stock and exercise of warrants. The company completed a one-for-thirty reverse stock split in September 2022.
- In December 2022, stockholders approved conversion of all Series A Preferred Stock, resulting in conversion into 12,333,333 common shares. Series B Preferred Stock also converted into common stock.
Guidance, Outlook, Risks and Unusual Items
- Management intended to initiate a Phase 2a study of DA-1241 for NASH in the third quarter of 2023 and planned to file an IND for DA-1726 in the second quarter of 2023.
- DA-1241 had completed Phase 1a and Phase 1b studies and was described as generally well tolerated. DA-1726 remained in preclinical development, with planned Phase 1 studies in healthy and obese volunteers.
- Dong-A is eligible for regulatory milestone payments of up to $138 million for DA-1241 and $178 million for DA-1726, commercial milestones, and single-digit royalties on future net sales. No milestone or royalty payments had been triggered at December 31, 2022.
- The company expects continuing losses and negative operating cash flow and may never achieve profitability. Additional financing may dilute existing stockholders or require debt, licensing or other restrictive arrangements.
- Clinical, regulatory, manufacturing and patient-enrollment risks are substantial. Neither primary product candidate had received regulatory approval, and there is no assurance that either will complete development or be commercialized.
- NeuroBo relies on Dong-A and other third parties for clinical development, manufacturing and related services. Dong-A is the sole manufacturer for DA-1241 and DA-1726 under the disclosed arrangements.
- As of March 2023, Dong-A beneficially owned approximately 45.7% of voting rights and could reach approximately 60.3% if its warrants were exercised, creating significant control and dilution risks.
- Nasdaq notified the company in February 2023 that it was not compliant with the $1.00 minimum bid-price requirement. The company was required to regain compliance by August 7, 2023, subject to Nasdaq rules.
- Management concluded that disclosure controls and internal control over financial reporting were not effective at year-end because of material weaknesses involving segregation of duties, system access, and supervision and review of financial reporting.
- The independent auditor issued an unqualified opinion on the financial statements but did not provide an opinion on internal control effectiveness because the company was not required to obtain an auditor attestation.
Most Important Facts to Verify
- Whether the planned DA-1241 Phase 2a study and DA-1726 IND filing occurred on the stated timelines and produced favorable regulatory or clinical updates.
- Current cash balance, quarterly cash burn and the timing and terms of any subsequent financing.
- Whether NeuroBo regained and has maintained Nasdaq minimum bid-price compliance.
- The extent of dilution from outstanding cashless warrants, stock options and future equity offerings.
- Whether the Dong-A relationship remains commercially and operationally favorable, including manufacturing dependence, related-party governance and potential milestone obligations.
- Progress in remediating the identified material weaknesses in internal control over financial reporting.
- Whether any legacy programs, particularly ANA001, NB-01, NB-02 or Gemcabene, have been licensed, discontinued or generated contingent obligations after the reporting date.